Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock Has Consensus Target Price of $40.86 According to Analysts

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have received a consensus rating of “Moderate Buy” from the nine analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $40.86.

Several brokerages have weighed in on LYEL. B. Riley Financial started coverage on shares of Lyell Immunopharma in a research note on Wednesday, July 22nd. They set a “buy” rating and a $44.00 price objective on the stock. Citigroup reiterated a “market outperform” rating on shares of Lyell Immunopharma in a research note on Friday, August 14th. Stifel Nicolaus assumed coverage on shares of Lyell Immunopharma in a research note on Thursday, August 6th. They issued a “buy” rating and a $36.00 target price for the company. Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a report on Friday, August 14th. Finally, HC Wainwright restated a “buy” rating on shares of Lyell Immunopharma in a research report on Friday, September 11th.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $10.88 on Tuesday. Lyell Immunopharma has a 52-week low of $7.20 and a 52-week high of $45.00. The business has a fifty day moving average of $10.93 and a two-hundred day moving average of $16.83. The stock has a market cap of $266.60 million, a PE ratio of -0.85 and a beta of -0.03.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, topping the consensus estimate of ($1.94) by $0.02. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%. The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Analysts predict that Lyell Immunopharma will post -7.16 earnings per share for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Opaleye Management Inc. raised its stake in shares of Lyell Immunopharma by 334.9% in the second quarter. Opaleye Management Inc. now owns 344,025 shares of the company’s stock worth $4,834,000 after acquiring an additional 264,928 shares during the last quarter. Squarepoint Ops LLC lifted its position in shares of Lyell Immunopharma by 119.4% during the second quarter. Squarepoint Ops LLC now owns 42,322 shares of the company’s stock worth $595,000 after purchasing an additional 23,028 shares in the last quarter. Velan Capital Investment Management LP grew its stake in shares of Lyell Immunopharma by 2.9% during the second quarter. Velan Capital Investment Management LP now owns 105,000 shares of the company’s stock valued at $1,475,000 after purchasing an additional 3,000 shares during the last quarter. venBio Partners LLC bought a new stake in shares of Lyell Immunopharma during the second quarter valued at approximately $4,744,643. Finally, Bank of New York Mellon Corp bought a new stake in shares of Lyell Immunopharma during the second quarter valued at approximately $347,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.

Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.